Background: Pain is a common and undertreated non-motor symptom in patients with Parkinson’s disease (PD). Opioids have been seldom used in PD because they could worsen cognitive and motor functions. Objective: We aimed to assess efficacy and tolerability of tapentadol in PD patients. Methods: We retrospectively reviewed 21 PD patients treated with tapentadol extended release (ER) for chronic pain. Patients were evaluated before treatment and at 3 and 6 months during treatment for pain intensity (current, 24-hour average, and minimum and worst) with a 0-10 Numerical Rating Scale and the painDETECT questionnaire; for motor symptom severity with the Unified Parkinson’s Disease Rating Scale part III and the Hoehn and Yahr scale; for cognitive functions with MiniMental Status Examination, Corsi’s Block Tapping test, Digit Span, Digit-Symbol Substitution test, FAS test, Rey’s Auditory Verbal Learning test, Trail Making-A and -B, and the 9 Hole-Peg Test; for anxiety and depression with the Hospital Anxiety and Depression Scale; and for the quality of life with the Short Form-12 for Quality of Life. Data were analyzed by one-way ANOVA and paired t-test, and by Friedman’s and Wilcoxon’s test. Statistical significance was taken in all cases as P < 0,05. Results: Pain intensity decreased over the course of treatment. No differences were found in PD symptom severity and dopaminergic drug dosages between pretreatment and treatment evaluations . No decrement in cognitive neuropsychological performances was found and an improvement was observed in Digit Span, Digit-Symbol Substitution test and FAS test. The levels of anxiety, depression and of quality of life improved. Overall tapentadol ER was well tolerated and most patients reported no or mild and short-lived gastroenterological and neurological side effects. Conclusions: These results indicate the potential efficacy and tolerability of medium-high dose of tapentadol ER for the treatment of pain in PD.

Effects of tapentadol on pain, motor symptoms and cognitive functions in Parkinson’s disease

Ulderico, Freo
;
Carlo, Ori.
2018

Abstract

Background: Pain is a common and undertreated non-motor symptom in patients with Parkinson’s disease (PD). Opioids have been seldom used in PD because they could worsen cognitive and motor functions. Objective: We aimed to assess efficacy and tolerability of tapentadol in PD patients. Methods: We retrospectively reviewed 21 PD patients treated with tapentadol extended release (ER) for chronic pain. Patients were evaluated before treatment and at 3 and 6 months during treatment for pain intensity (current, 24-hour average, and minimum and worst) with a 0-10 Numerical Rating Scale and the painDETECT questionnaire; for motor symptom severity with the Unified Parkinson’s Disease Rating Scale part III and the Hoehn and Yahr scale; for cognitive functions with MiniMental Status Examination, Corsi’s Block Tapping test, Digit Span, Digit-Symbol Substitution test, FAS test, Rey’s Auditory Verbal Learning test, Trail Making-A and -B, and the 9 Hole-Peg Test; for anxiety and depression with the Hospital Anxiety and Depression Scale; and for the quality of life with the Short Form-12 for Quality of Life. Data were analyzed by one-way ANOVA and paired t-test, and by Friedman’s and Wilcoxon’s test. Statistical significance was taken in all cases as P < 0,05. Results: Pain intensity decreased over the course of treatment. No differences were found in PD symptom severity and dopaminergic drug dosages between pretreatment and treatment evaluations . No decrement in cognitive neuropsychological performances was found and an improvement was observed in Digit Span, Digit-Symbol Substitution test and FAS test. The levels of anxiety, depression and of quality of life improved. Overall tapentadol ER was well tolerated and most patients reported no or mild and short-lived gastroenterological and neurological side effects. Conclusions: These results indicate the potential efficacy and tolerability of medium-high dose of tapentadol ER for the treatment of pain in PD.
2018
File in questo prodotto:
File Dimensione Formato  
Freo Tap for PD JPS2018.pdf

accesso aperto

Tipologia: Preprint (submitted version)
Licenza: Accesso libero
Dimensione 734.23 kB
Formato Adobe PDF
734.23 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/3270940
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 16
social impact